This article was originally published in The Tan Sheet
Ingredient supplier's $716,000 fourth quarter net income reflects positive impact of cost savings in SG&A, renewed focus on R&D efforts for core businesses, firm says. Full year net income fell 84% to $1.1 mil. Results reflect Chromax chromium picolinate price adjustments, Q2 restructuring charges, partially offset by positive impact of favorable settlements of patent-infringement lawsuits, initial licensing fees for nisin, lysostaphin technologies, Nutrition 21 reports
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC